Jeffrey Rakofsky is a Psychiatry physician affiliated with Emory University. OpenAlex indexes 79 publications with 1,821 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2004 Ridgewood Dr NE
Suite 218
Atlanta, GA 303221031
Telephone
404-727-5157Registry record last updated 31 Jan 2008.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme CorporationProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
94.5%Atypical Antipsychotic19.2%Quetiapine Fumarate34%Aripiprazole23%Olanzapine14%Clozapine14%Risperidone5%Lurasidone Hcl5%Vraylar5%Part D<11 patientsSSRI13.3%Trazodone Hcl30%Escitalopram Oxalate25%Fluoxetine Hcl23%Sertraline Hcl15%Citalopram Hbr8%Part D<11 patients+ 12 more classes in this area
Hormonal (systemic)
3.3%l-Thyroxine3.3%Levothyroxine Sodium100%Part D<11 patientsCardiovascular
2.2%Beta blocker2.2%Propranolol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults
Journal of Psychopharmacology
2022 - Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation
The Journal of Clinical Psychiatry
2022 - Lithium in the treatment of acute bipolar depression: A systematic review and meta-analysis
Journal of Affective Disorders
2022 - The United States index of socioeconomic deprivation for individuals (USiDep)
Personalized Medicine in Psychiatry
2022
Similar KOLs
Other experts from the same institution or the same specialty.
James Lah, MD
Emory University
Keith Delman, MD
Emory University
John Puskas, MD
Emory University
Craig Hofmeister, MD
Emory University
Charles Nemeroff, MD
Dell Medical School
Maurizio Fava, MD
Massachusetts General Hospital
John Krystal, MD
Yale University
Jeffrey Lieberman, MD
Columbia University College of Physicians and Surgeons
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”